Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ROCKVILLE, Md., July 20, 2026 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation announce the creation of a new resource for IgA nephropathy patients and...
-
ROCKVILLE, Md., July 20, 2026 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and the IgA Nephrology Foundation announce the creation of a new resource for IgA nephropathy patients and...
-
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
-
New York, USA, June 25, 2026 (GLOBE NEWSWIRE) -- IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight The IgA nephropathy clinical trial analysis...
-
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgAN
-
New York, USA, April 29, 2026 (GLOBE NEWSWIRE) -- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight The IgAN market is growing due to...
-
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
-
Exton, PA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Two months following the U.S. approval of Voyxact (sibeprenlimab) for IgA nephropathy (IgAN), new data from Spherix Global Insights indicate rapid early...
-
Vera Therapeutics to participate in the 44th Annual J.P. Morgan Healthcare Conference
-
Vera Therapeutics' management team will present at the TD Cowen Immunology & Inflammation Summit (Nov. 12-13, 2025).